

Cited in: EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.

Reviews

The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group

R.M. MacRae (Canada), M. Ashton (United Kingdom), O. Lauk (Switzerland), W. Wilson (Australia), N. O'Rourke (United Kingdom), C.B. Simone II, A. Rimner (USA) 24

Original Research Articles

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)

M. Fukuda, T. Kitazaki, D. Ogawara, M. Ichiki, H. Mukae, R. Maruyama, N. Nakagaki, M. Shimada, T. Ikeda, J. Kishimoto, T. Harada, T. Seto, N. Ebi, K. Takayama, I. Okamoto, Y. Ichinose, K. Sugio (Japan) 1

High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors

G.J. Lee, H. Lee, I.S. Woo, T. Kim, H.J. An, H.J. Choi, Y.S. Lee, K.Y. Lee, J. Lee, J.-H. Kang (South Korea) 9

Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial

M. Platania, F. Pasini, L. Porcu, M. Boeri, F. Verderame, Y. Modena, A. Del Conte, F. Nichetti, M.C. Garassino, A. Martinetti, E. Sottotetti, L. Cavanna, E. Vattemi, D. Pozzessere, A. Bertolini, L. Irtelli, C. Verri, G. Sozzi, C. Proto, U. Pastorino, V. Torri, A.P. Fraccon, F. Spinnato, D. Signorelli, G. Lo Russo, A. Tuzi, R. Gallucci, S. Cinieri, M. Mencoboni, P. Antonelli, L. Giacomelli, F. de Braud (Italy) 17

Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology

W. Tu, G. Sun, L. Fan, Y. Wang, Y. Xia, Y. Guan, Q. Li, D. Zhang, S. Liu, Z. Li (China) 28

Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases

M.-C. Zhang, M. Zhou, Q. Song, S. Wang, Q. Shi, L. Wang, F.-h. Yan, J.-M. Qu, W.-L. Zhao (China) 39

Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors

S. Cui, Y. Ni, Y. Zhao, Z. Li, L. Xiong, J. Liu, X. Liang, L. Jiang (PR China) 45

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

E. Ichihara, K. Hotta, K. Ninomiya, T. Kubo, K. Ohashi, K. Rai, H. Tanaka, M. Tabata, Y. Maeda, K. Kiura (Japan) 54

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

S. Assoun, N. Theou-Anton, M. Nguenang, A. Cazes, C. Danel, B. Abbar, J. Pluvy, V. Gounant, A. Khalil, C. Namour, S. Brosseau, G. Zalcmann (France) 65

(Contents continued overleaf)



Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer G. Galli, T. Triulzi, C. Proto, D. Signorelli, M. Imbimbo, M. Poggi, G. Fucà, M. Ganzinelli, M. Vitali (Italy), D. Palmieri, A. Tessari (USA), F. de Braud, M.C. Garassino, M.P. Colombo, G. Lo Russo (Italy)	72
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis C.H. Suh, K.W. Kim (Republic of Korea), J. Pyo (the Netherlands), H. Hatabu, M. Nishino (USA)	79
Demography, patterns of care and survival outcomes in patients with malignant tumors of trachea: A systematic review and individual patient data analysis of 733 patients S. Mallick, R. Benson, P. Giridhar, A. Rajan Singh, G.K. Rath (India)	87
Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma I. Berger, K.A. Cengel, C.B. Simone II, E.W. Alley, L. Roshkovan, A.R. Haas, A.M. Patel, U. Khalid, M.J. Culligan, S. McNulty, S. Singhal, J.S. Friedberg, S.I. Katz (United States)	94
The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP J.K. Yoo, J.M. Lee, S.H. Kang, S.H. Jeon, C.M. Kim, S.-H. Oh, C.-H. Kim, N.K. Kim, J.K. Kim (Republic of Korea)	99
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab J. Oyanagi, Y. Koh, K. Sato, K. Mori, S. Teraoka, H. Akamatsu, K. Kanai, A. Hayata, N. Tokudome, K. Akamatsu, M. Nakanishi, H. Ueda, N. Yamamoto (Japan)	107
Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening F. Liang, C. Wu, H. Gu, M. Zhu, Z. Xuan, Y. Jiang, H. Chen, C. Fu, Y. Zheng (China)	114
Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC) G. Minniti, C. Scaringi, G. Lanzetta, D. Anzellini, F. Bianciardi, B. Tolu, R. Morace, A. Romano, M. Osti, P. Gentile, S. Paolini (Italy)	119
Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells J. Vad-Nielsen, K.R. Gammelgaard, T.F. Daugaard, A.L. Nielsen (Denmark)	132
Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence V. Grøndahl, T. Binderup, S.W. Langer, R.H. Petersen, K. Nielsen, A. Kjaer, B. Federspiel, U. Knigge (Denmark)	141
<i>Short Communications</i>	
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma H. Wang, J. Agulnik, G. Kasymjanova, P.O. Fiset, S. Camilleri-Broet, M. Redpath, V. Cohen, D. Small, C. Pepe, L. Sakr, A. Spatz (Canada)	36
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer K. Park (South Korea), J. Bennouna (France), M. Boyer (Australia), T. Hida (Japan), V. Hirsh (Canada), T. Kato (Japan), S. Lu, T. Mok (China), K. Nakagawa (Japan), K. O'Byrne (Australia), L. Paz-Ares (Spain), M. Schuler (Germany), D.M. Sibilot (France), E.-H. Tan (Singapore), H. Tanaka (Japan), Y.-L. Wu (China), J.C.-H. Yang (Taiwan), L. Zhang, C. Zhou (China), A. Märten (Germany), W. Tang (USA), N. Yamamoto (Japan)	126
<i>Case Reports</i>	
Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events K. Kunimasa, H. Nakamura, K. Sakai, M. Tamiya, M. Kimura, T. Inoue, K. Nishino, H. Kuhara, S.-i. Nakatsuka, K. Nishio, F. Imamura, T. Kumagai (Japan)	59
<i>Correspondence</i>	
Comment on: 'Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas' T. Song, L. Jiang, Y. Lin (China)	150
Response to comment on: "Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas." M.-S. Hsieh (Taiwan), M.-W. Lin (Taiwan)	151

What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? S. Bravaccini (Italy)	152
Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer S. Lan, H. Li, Y. Liu, L. Ma, X. Liu, Y. Liu, S. Yan, Y. Cheng (China)	154
<i>Corrigenda</i>	
Corrigendum to “Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan” [Lung Cancer, 129 (March) (2019) 55-62] S. Watanabe, H. Yoshioka, H. Sakai, K. Hotta, M. Takenoyama, K. Yamada, S. Sugawara, Y. Takiguchi, Y. Hosomi, K. Tomii, S. Niho, N. Yamamoto, M. Nishio, Y. Ohe, T. Kato, T. Takahashi, A. Kamada, K. Suzukawa, Y. Omori, S. Enatsu, K. Nakagawa, T. Tamura (Japan)	157
Corrigendum to “Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis” [Lung Cancer, Volume 130 (April) (2019) 162-168] C.C. Foster, C.G. Rusthoven, D.J. Sher, L. Feldman, M. Pasquinelli, M.T. Spiotto, M. Koshy (USA)	159
Corrigendum to “Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer” [Lung Cancer 121 (July) (2018) Pages 37-40] M. Nishio, K. Nakagawa, T. Mitsudomi, N. Yamamoto, T. Tanaka, H. Kuriki (Japan), A. Zeiter (Switzerland), T. Tamura (Japan)	160